-
MedTech Company BioSig Technologies Deploys Disruptive Technology To Improve Arrhythmia Care
This article was previously published to Benzinga. Arrhythmia is a heart condition that causes it to beat either too fast, or irregularly. It’s triggered by abnormal electrical activity and affects the heart’s rhythm, leading it to beat out of sync with the rest of the body. Not every patient experiences arrhythmia in the same way, so it’s sometimes necessary for doctors to provide each patient with a personalized approach to treatment and recovery. Lifestyle choices and comorbidities, medication, stress and environmental factors can cause the heart to beat out of sync. The world is experiencing an uptick in arrhythmia cases linked to the after effects of COVID-19. Atrial fibrillation (AFib) is the…
-
Biotricity Invites Physicians to Join Shared Revenue Opportunity, Provides Clinics with Remote Devices for Improved Monitoring and Diagnosis
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Ranked as one of the fastest-growing companies in the healthcare sector, Biotricity Inc. (NASDAQ: BTCY) sets out to leave an imprint on all 50 states with its connected, real-time monitoring medtech device. For the last 19 months, Dr. Waqaas Al-Siddiq, CEO, chairman and founder of Biotricity, has led his company to list on a major exchange and expand into 23 different states across the U.S. The company’s flagship device — the Bioflux — is a wearable that gives doctors and cardiologists the ability to monitor and diagnose…
-
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
Previously Published on Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lineage Cell Therapeutics Inc. (AMEX: LCTX) recently provided an update on its lead program OpRegen®, a cell replacement therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA). Lineage is pioneering a new branch of medicine, which is manufacturing differentiated cell types and transplanting those cells into the body, to restore or improve function which has been lost due to injury or disease. The data from an ongoing Phase 1/2a clinical study continued to demonstrate that a single administration of OpRegen, an investigational cell therapy consisting of…
You May Also Like
Why Is There a Renewed Interest in Hemp by Textile and Manufacturing Companies?
Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2
Biotricity Invites Physicians to Join Shared Revenue Opportunity, Provides Clinics with Remote Devices for Improved Monitoring and Diagnosis
-
Biotricity Continues to Transform the Way We Do Health: Medtech Launches New Biokit Solution, Aims at Personal Health Monitoring
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Biotricity (NASDAQ: BTCY) is reforming the healthcare market as one of the fastest-growing companies in medtech. The company bridges the gap in remote cardiac monitoring, preventive and chronic care management by using the power of IoT (internet of things), wearables, and connected devices. Not only does the company offer real-time, comprehensive monitoring and diagnostic services for cardiac-related healthcare and comorbidities, but its devices are also built with features that can dispatch emergency care services should any anomalies or arrhythmias occur when a device is worn. …
-
Biotricity Reports Q1 Earnings at 290% for FY2022
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Biotricity (NASDAQ: BTCY) has been taking the world of medtech by storm, introducing primary care providers across the country to its remote heart monitoring devices. Always connected, these wearable devices have been giving power back to those suffering from chronic cardiac conditions and simultaneous comorbidities — the simultaneous presence of two or more diseases or medical conditions and often relative of one another. Through remote heart monitoring and diagnostic technologies, doctors can screen their patients from a distance, even alerted to a possible emergency if the…
